Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer

This study is designed to determine if treatments with the combination of HRS-8080 and SHR-A1811, the combination of HRS-8080 and SHR-A2009, the combination of SHR-A2009 and SHR-1316 are safe, tolerable, and has anti-cancer activity in patients with unresectable or metastatic breast cancer.

Trial Details

NCT ID

NCT06222879

Phase

PHASE1 / PHASE2

Sponsor

Shandong Suncadia Medicine Co., Ltd.

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

HRS-8080; SHR-A1811
HRS-8080; SHR-A2009
SHR-A2009; SHR-1316

Locations (sample)

Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

Females aged 18-75 years old (both ends inclusive);
ECOG performance status (PS) 0-1 points;
Patients with metastatic or locally advanced breast cancer confirmed by histology（ER positive, HER2 positive/negative，or triple negative breast can…
Tumor tissue samples must be provided for detection of tumor markers;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →